PORT WASHINGTON, N.Y.--(BUSINESS WIRE)--CB1 Capital Management LLC, the New York-based investment adviser that invests in the supply chain of cannabinoid-based solutions, products and therapies that address a wide range of unmet medical or physiological conditions or commercial use-cases, is pleased to announce the addition of Dr. Jeffrey Chen to its Advisory Board.

Dr. Jeff Chen MD/MBA is an impact entrepreneur and scientist. At 29, he founded the UCLA Cannabis Research Initiative, one of the first such programs in the world. As Executive Director, he grew the program to over 40 faculty across 18 UCLA departments working on cannabis and hemp-related research, education, and policy projects. Dr. Chen has been a co-founder, managing partner, investor, and advisor to companies, not-for-profits, and venture firms in the life science, sustainability, tech, and media sector. He is a David Geffen Fellow, U.S. patent holder, Mentor for U.S. National Institutes of Health Innovation CORPs, and part of the Medical Team at Healthline. Dr. Chen earned his MD and MBA concurrently at UCLA on a full merit scholarship, and his B.S. from Cornell.

“I’m excited to join my esteemed colleagues on the CB1 Capital Management Advisory Board and I look forward to continuing to uncover the therapeutic applications of cannabinoids,” said Dr. Chen, who is currently the Cofounder/CEO of Radicle Science, a health tech company accelerating clinical trials on natural medicines.

“We’re honored to have Dr. Chen join our advisory board as we further our commitment toward better understanding the science that will drive cannabis 3.0, or efficacy-driven solutions, as research opens in 2021 and beyond,” said Todd Harrison, founding partner and chief investment officer of CB1 Capital Management, adding, “Jeff is a visionary.”

The other members of the CB1 advisory board include:

Lorne Gertner: chairman of HG2 Capital Corp; CEO of Hill & Gertner Capital Group; co-founder, The Cronos Group; director, Emblem Corp.; co-founder and chairman of Tokyo Smoke; investment partner and director, Green Acre Capital; director, Hempco Food & Fiber.

Dr. Julie Holland, an American psycho-pharmacologist, psychiatrist, and author, she is the author of five books and an advocate for the appropriate use of consciousness expanding substances as part of mental health treatment. She is a medical monitor for MAPS studies, which involve, in part, developing psychedelics into prescription medication.

Gary Johnson: 29th governor of New Mexico; two-time presidential candidate; founder, Big J Enterprises; former CEO of Cannabis Sativa Inc.

Dr. Ethan Russo: board-certified neurologist; psychopharmacology researcher; Founder and CEO of CReDO Science; Former senior medical advisor, GW Pharmaceuticals.

About CB1 Capital Management LLC

Based in New York, CB1 Capital Management LLC is an investment adviser that invests in securities of companies in the cannabinoid-wellness space. Nothing contained in this release is intended as a solicitation to invest.